TY - JOUR T1 - Juvenile idiopathic arthritis and risk of cancer before and after the introduction of biological therapies JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2019-001055 VL - 5 IS - 2 SP - e001055 AU - AnnaCarin Horne AU - Bénédicte Delcoigne AU - Karin Palmblad AU - Johan Askling Y1 - 2019/11/01 UR - http://rmdopen.bmj.com/content/5/2/e001055.abstract N2 - Background The risk of cancer, including any secular trends in risk, in patients with juvenile idiopathic arthritis (JIA) is incompletely understood.Methods We performed a register-based cohort study of patients with JIA from 2001 until 2017, identified via the Swedish Patient Register. Patients with JIA were matched to five population reference subjects. Patients and referents were followed up for incident cancers (via linkage to the Swedish Cancer Register) until 18 years of age or 31 December 2016.Results Among the 6721 patients with JIA, we observed 10 incident malignancies (5 lymphoproliferative cancers) during 34 951 person-years of follow-up, corresponding to an excess incidence of 0.09 cancers per 1000 person-years (one extra case per 11 000 patients per year), an HR for cancer (all sites) of 1.4 (95% CI 0.7 to 2.9) and an HR for lymphoproliferative malignancies of 3.6 (95% CI 1.1 to 11.2). The rates of cancer in JIA did not increase over the study period. We noted no differences in the excess risk comparing periods before and after the introduction of biologic disease-modifying antirheumatic drugs (bDMARDs).Discussion Children and adolescents with JIA are at a slightly increased risk of lymphoproliferative (but not of other) malignancies. At the group level, there is no sign that this risk has increased further after the introduction of bDMARDs. ER -